Biocytogen Pharmaceuticals (Beijing) Employees

Biocytogen Pharmaceuticals (Beijing) had 1,117 employees as of December 31, 2024. The number of employees increased by 51 or 4.78% compared to the previous year.

Employees

1,117

Change (1Y)

Growth (1Y)

4.78%

Revenue / Employee

999.22K HKD

Profits / Employee

110.93K HKD

Market Cap

12.86B

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	1,117	51	4.78%
Dec 31, 2023	1,066	-282	-20.92%
Dec 31, 2022	1,348	-	-

Related Stocks

Company Name	Employees
BeOne Medicines AG	11,000
Hansoh Pharmaceutical Group Company	8,989
JD Health International	3,564
Innovent Biologics	5,659
WuXi Biologics	12,575
Sino Biopharmaceutical	24,379
Akeso	3,035
Sichuan Kelun-Biotech Biopharmaceutical	1,837

Employee Rankings

Biocytogen Pharmaceuticals (Beijing) News

3 months ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
4 months ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
5 months ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
6 months ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
6 months ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn
6 months ago - Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Financial Post
11 months ago - Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors - Financial Post

More News